A 12-Week Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX 160/4.5 mcg Inhalation Powder Versus SYMBICORT TURBOHALER 200/6 mcg in Adult and Adolescent Patients with Persistent Asthma

Trial Profile

A 12-Week Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX 160/4.5 mcg Inhalation Powder Versus SYMBICORT TURBOHALER 200/6 mcg in Adult and Adolescent Patients with Persistent Asthma

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jul 2015

At a glance

  • Drugs Budesonide/formoterol (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Sponsors Teva Branded Pharmaceutical Products R&D; Teva Pharmaceutical Industries
  • Most Recent Events

    • 01 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Feb 2014 This study is expected to report in 2014, but is not required to be completed to gain final approval for DuoResp Spiromax from the European Commission, according to a Teva Pharmaceutical Industries media release.
    • 09 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported in United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top